Kornimate/medical-research-clean huggingface dataset:
administering nmt to reestablish infant nasal microbiome diversity following intranasal mupirocin treatment

Conditions: Staphylococcal Aureus Infection; Microbial Colonization; Pediatric Infection; S. Aureus Colonization; Microbial Transplant

Summary: this protocol aims to evaluate how nmt affects pediatric nasal microbiome diversity following intranasal mupirocin treatment

this parent-to-child nmt study will test the effect of an anterior nares, or nasal, microbiota transplant (nmt) on seeding, engraftment, and diversity of the neonatal microbiome following nasal decolonization for s. aureus. infants admitted to the johns hopkins neonatal intensive care unit (nicu) will be screened and parents will be approached for enrollment in the study. after consent and baseline screening of parents and infants, eligible infants will undergo an nmt.

Eligibility criteria:
infant: * inclusion criteria 1. infant has had a prior nasal surveillance culture grow s. aurues 2. infant being treated with intranasal mupirocin for s. aureus nasal colonization as part of routine clinical care 3. infant has anticipated hospital length of stay \>3 days after completing intranasal mupirocin treatment 4. infant \>25 weeks gestation 5. at least one donor not colonized with s. aureus or another respiratory pathogen (as determined by baseline screening) * exclusion criteria 1. infant is a ward of the state 2. infant with antenatal suspicion for immunodeficiency (e.g. sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency) 3. infant cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing) parent/adult provider: * inclusion criteria 1. donor is able to provide informed consent * exclusion criteria 1. donor had positive covid-19 test in prior 21 days 2. donor with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough) 3. donor has been in close contact with someone in the last 7 days who had a respiratory viral infection (e.g., cold, flu) 4. donor tests positive on baseline screening test for s. aureus nasal colonization. 5. donor tests positive on baseline screening test for a respiratory pathogen. 6. donor is not able to provide written informed consent 7. donor is not able to be present at the bedside at the time of intervention. 8. donor has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism. 9. inability or unwillingness to complete the donor questionnaire or a positive response to any question on the donor questionnaire. 10. donor has smoked within the last month

Keywords: microbiome s. aureus staph
first-in-human safety and immunogenicity study of scb-1022 and scb-1033 in healthy older adults

Conditions: Respiratory Syncytial Virus Vaccination; Human Metapneumovirus Vaccination; Parainfluenza Vaccination

Summary: this phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of scb-1022 and scb-1033 in healthy adults aged 60-85 years.

the study will descriptively evaluate three dose levels of scb-1022 and scb-1033. the sample size for this study is not based on formal statistical hypothesis testing but is acceptable for safety and immunogenicity evaluation in a phase 1 study. the study will be overseen by a safety monitoring committee.

Eligibility criteria:
inclusion criteria: * male and female participants 60 to 85 years of age at the screening visit. * individuals willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures. * individuals willing and able to give an informed consent, prior to screening. * healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator; participants with pre-existing stable medical conditions can be included. please refer to protocol for full list of inclusion and exclusion criteria. exclusion criteria: * pregnancy or potential to become pregnant during the study. * acute disease or fever (≥38°c) at time of vaccination. * history of guillain-barré syndrome (gbs). * recurrent or un-controlled neurological disorders or seizures. * serious or unstable chronic illnesses. please refer to protocol for full list of inclusion and exclusion criteria.

Keywords: respiratory syncytial virus vaccination human matapneumovirus vaccination parainfluenza vaccination healthy volunteers
efficacy and safety of emodepside in adults infected with trichuris trichiura and hookworm

Conditions: Trichuris Trichiura; Infection; Hookworm Infections

Summary: the rationale of the study is to provide evidence on the efficacy and safety of emodepside in adults infected with trichuris trichiura and hookworm.


Eligibility criteria:
inclusion criteria: * male or female adults aged between 18 and 45 years * written and signed informed consent * examined by a study physician before treatment * provided two stool samples at baseline * trichuris trichiura and hookworm epg ≥ 48 and at least two kato-katz thick smears slides with more than one trichuris trichiura and hookworm eggs exclusion criteria: * pregnant or lactating and/or planning to become pregnant within three months after drug treatment * type 1 and/or 2 diabetes * psychiatric disorders * history of ophthalmological conditions * presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment * suffers from severe anaemia (hb \< 80 g/l) * received anthelminthic treatment within past four weeks * attending other clinical trials during the study * received strong cyp3a4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for cyp3a4 such as clarithromycin, erythromycin and rifampicin * received strong p-gp inhibitors as well as concomitant treatments that are relevant substrates for p-gp such as clotrimazole and ritonavir

Keywords: emodepside trichuris trichiura hookworm soil-transmitted helminths efficacy safety dose selection
cannabis use disorder treatment study

Conditions: Cannabis Use Disorder, Mild; Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe

Summary: the purpose of this study is to test a text-delivered counseling program to stop or reduce cannabis use among young adults (ages 18 to 25).

after being informed about the study and potential risks, participants will complete online screening assessments. those who are determined to be eligible via online screening will complete a urine drug screen to confirm eligibility. once eligibility is confirmed, participants will be randomized either to the intervention group or to the wait-list control group. those who are randomized to the intervention group will receive the 4-week text intervention via smartphone and complete assessments (including urine drug screens) at baseline, 1 month, 3 months, and 6 months. those who are randomized to the wait-list control group will only complete the assessments (including urine drug screens) at baseline, 1 month, 3 months, and 6 months. participants who are initially assigned to the wait-list control group can choose to receive the text intervention once their 6-month participation is complete.

Eligibility criteria:
inclusion criteria: 1. 18 to 25 years old. 2. use of cannabis three or more days during a typical week. 3. a score of at least eight on the cannabis use disorder identification test-revised 4. a urine specimen positive for cannabis metabolites. 5. a score of at least two on the mini international neuropsychiatric interview: version 7.0.2 for dsm-v, substance use disorder 6. must live in tennessee or colorado exclusion criteria: 1. substance abuse treatment during the past three months. 2. lack of access to a text-capable phone. 3. unable or unwilling to commit to six months of follow-up. 4. not fluent in english.
virtual reality for improving symptoms in palliative care

Conditions: Cancer and Non-cancer Hospice Patients

Summary: the objective of this study is to determine whether vr can ameliorate symptoms for palliative care patients within a hospice setting. we also aim to verify the efficacy with a larger sample size than previously shown, as well as extend the population to include non-cancer patients receiving hospice care. we will further attempt to delineate whether there is a sustainability of symptomatic improvement one week after vr experiences.

potential candidates will be provided with our assent and consent information form and the study will be explained to them in detail prior to gaining consent. as per standard practice at the hospice of windsor \& essex county, palliative care esas symptoms will be measured at baseline during the week prior to the vr experience. the mean of these pre-vr scores will be calculated as a baseline, optimally 3 separate esas scores in the preceding week. esas symptoms and expectations/satisfaction will then be measured immediately before and after the vr experience. an average set of esas scores will then be calculated in the same manner for one week post vr as per baseline pre-vr scores above. we expect to find a decrease in palliative care symptoms after the intervention of a vr experience.

Eligibility criteria:
inclusion criteria: * at least 18 years or older * admitted to hospice for specialty palliative care exclusion criteria: * palliative performance scale (pps) ≤ 20% * severe cognitive impairment leading to inability to provide esas scores for 5 key symptoms measured in this study * severe visual and/or hearing impairment preventing use of vr (glasses and hearing aids may be worn during vr sessions and do not exclude participation) * absolute inability to sit * paralysis of an upper limb * participant dies before vr experience

Keywords: virtual reality palliative care edmonton symptom assessment scale hospice depression anxiety pain shortness of breath well-being
covid-19 search in conjunctival cells

Conditions: COVID 19; Pulmonary Disease

Summary: the patients enrolled in this study will be all patients entering triage with suspicion of sars-cov2. planned activities are required by the nasopharyngeal swab in parallel with the analysis of the conjunctival swab to identify new potential alternative and equally effective diagnostic pathways. simultaneously systemic data (as pulmonary images, hematological parameters etc.) will be collected to observe a possible correlation between conjunctival swab positivity and systemic impairment.

in recent months, considerable interest has turned to coronavirus infection in terms of early diagnosis and targeted therapy. thanks to the experimentation of new therapeutic strategies, it becomes more and more evident how some subgroups of patients can benefit from a specific treatment, while others would have no benefit. alongside these innovative clinical research techniques, early diagnosis that would lead to identifying those at risk of a new disease and new infection is becoming increasingly important. covid-19 occurred in china in december 2019 but probably already had an expression in the previous months. the number of victims reached its peak in january 2020 with prevalent involvement of patients already at risk or with previous physical debilitations. but even apparently healthy and young individuals can be affected by infections with a lethal outcome. since january 2020 new cases have been registered all over the world and prevalently in italy. the main way of infection identified is the respiratory tract, but infection through conjunctival may not be excluded. the main outcome of this research is to investigate the positivity of the covid-19 virus in the conjunctival mucosa to establish a new diagnostic target. all patients will receive both the conjunctival swab and nasopharyngeal swab. the conjunctival swab will be performed in each eye and both swabs will be inserted into the same virus test tube. the swab samples will be sent in the same day to the microbiology laboratory for examination by real time-pcr. the secondary outcome will be to evaluate the possible positivity of the conjunctival swab with the degree of systemic impairment. this objective has the purpose of personalized medicine.

Eligibility criteria:
inclusion criteria: * all patients accepted to triage with positivity or suspected positivity to covid-19 will be enrolled in the study and both conjunctival and nasopharyngeal swab will be performed. exclusion criteria: * to date, there are no exclusion criteria

Keywords: conjunctival swabs diagnosis sars-cov2 systemic impairment
study assessing the safety and efficacy of de-117 ophthalmic solution once daily and twice daily in subjects with primary open-angle glaucoma spectrum 6

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension

Summary: this is a randomized, double-masked, parallel-group, multi-center study. subjects diagnosed with poag or oht who meet eligibility criteria at visit 1 (screening) will wash out their current topical iop lowering medication(s), if any. after completing the required washout period, subjects will return for visit 2 (baseline, day 1). subjects who meet all eligibility criteria at visit 2 (baseline, day 1) will be randomized to receive study medication for up to 6 weeks. approximately 100 subjects with poag or oht will be randomized in a 1:1 ratio to either: * de-117 ophthalmic solution 0.002% qd (once daily) * de-117 ophthalmic solution 0.002% bid (twice daily) this study will consist of a screening period of up to 35 days including a washout period of up to 28 days (+ 7 days window), and a 6-week double-masked treatment period.


Eligibility criteria:
inclusion criteria: provide signed written informed consent * have a diagnosis of poag or oht in both eyes, or one eye with poag and the other with oht. * qualifying corrected visual acuity in each eye * qualifying central corneal thickness in each eye * qualifying day 1 iop measurement at 3 time-points in both eyes * qualifying anterior chamber angle exclusion criteria: * history of ocular surgery specifically intended to lower iop * subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period * advanced glaucoma in either eye * any corneal abnormality or other condition interfering with or preventing reliable goldmann applanation tonometry * any ocular surgery or ocular laser treatment within 180 days prior to screening and throughout the study in either eye * females who are pregnant, nursing, or planning a pregnancy
relationship between serum n/ofq and brain-heart syndrome

Conditions: Cerebral-Cardiac Syndrome

Summary: choosing the neurology patients in the second hospital of shanxi medical university, diagnosed with patients with cerebral syndrome into the experimental group; patients who did not have cerebral syndrome included in the control group, and all selected people had no intimate relationship with each other.specimen collecting control group and the study group serum inflammatory factor il-6, solvent peptide and catecholamine content. the difference between the two groups of data was observed.according to the literature, it is guess: the solitary peptide content of the experimental group will be higher than the control group, and is positively correlated with il-6, catecholamine content.the difference was statistically significant.


Eligibility criteria:
inclusion criteria: * diagnostic criteria in compliance with cerebral syndrome * acute ischemic stroke patients in line with the "chinese acute ischemic stroke treatment guide 2018" related diagnostic criteria * there is no intimate relationship between all selected people and knows this study, and signs informed consent exclusion criteria: * heart-type cerebral infarction, hemorrhagic stroke, brain tumor and past intracranial hemorrhage * complicated with severe cardiovascular complications (such as coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic heart failure, atrial fibrillation, etc.) * complicated with severe liver and kidney dysfunction (such as coagulous dysfunction, cirrhosis, nephrotic syndrome , renal failure, etc.) * complicated with severe diabetes complications (such as diabetic nephropathy, diabetic foot, diabetic acidosis, high blood sugar hypertonic state, diabetes coronary heart disease, etc.) * complicated with psychological disease * complicated with chronic obstructive pulmonary disease(copd) * bmi\> 40
learning diagnostic skills online (german: diagnostik skills online lernen)

Conditions: Diagnosis, Psychiatric

Summary: clinical psychologists give diagnoses to their patients everyday and these diagnoses determine if and how these patients will be treated. misdiagnoses can have severely adverse effects. therefore, teaching diagnostic skills to clinical psychologists is very important during their undergraduate, graduate and postgraduate training. one major problem in teaching diagnostics is that there are too few opportunities to practice with real patients due to legal and ethical restrictions. the aim of the disko-project is, therefore, the development and evaluation of a blended learning course to teach diagnostic skills to (future) clinical psychologists. in order to make the diagnostic training more practical a series of video files of simulated diagnostic interviews will be presented in an online course. these video files will be divided in different segments and presented with questions and automatic feedback. in a second step, learners will make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient. the disko- course will be evaluated in a randomized-controlled trial at three universities in germany (ruhr-university of bochum, philipps university of marburg, university of cologne). to test whether students are equally good in administering a diagnostic interview after taking the disko-course compared to students who took part in a traditional face-to-face university course a noninferiority-analysis will be conducted. furthermore, diagnostic knowledge and attitudes toward evidence-based assessment after taking part in disko vs. the face-to-face course will be compared. the investigators aim at disseminating the open source disko-course to other universities or institutions of tertiary education in germany with the aim of improving the diagnostic training for students, better prepare them for their clinical practice and thus improve patients' health care in germany.


Eligibility criteria:
inclusion criteria: * psychology bachelor students of a cooperating university (ruhr-university of bochum, university of cologne, philipps-university of marburg) exclusion criteria: * previous participation in a diagnostic seminar

Keywords: clinical interview blended learning diagnostic interview
precision allergy: separate allergies to male and female dogs

Conditions: Allergy; Dander

Summary: a new male-specific dog-allergen-component has been found (can f 5) which indicates possible differences in allergic reactions to male and female dogs. this has not yet been tested in real life. the aim is to test if sensitization only to the male-dog specific allergen-component, can f 5, results in a positive skin prick test (spt) to male dog extract and not female dog extract. in addition, the investigators want to investigate if allergic symptoms only occur when exposed to the male dog extract by conjunctival provocation.


Eligibility criteria:
inclusion criteria: * participants in the copsac 2000 cohort * positive component test (\>0.3 isu) to can f 1, can f 2, can f 3 or can f 5 exclusion criteria: * uncontrolled asthma * eye-surgery within the past 6 months * antihistamine allergy * and others

Keywords: dog allergy can f 5 male dog female dog allergen components
does menopause matter?

Conditions: Menopause

Summary: the purpose of this study is to follow a woman's progression through menopause in order to examine the effects on health related quality of life and use of health care resources, and to understand how women are using alternative therapies.

menopause affects every woman as she ages, yet every woman's experience is different. we are seeking to enroll 720 women from the university of pittsburgh's division of general internal medicine outpatient practice (gimo) at all stages of menopause (pre-, peri-, and post-menopausal), between 40 and 65 years old. they will be followed for 5 years as they progress through menopause. women will complete yearly questionnaires during their usual doctor's visit (or by phone or online if necessary) regarding general health, menopause and menopausal symptoms, health related quality of life, traditional and alternative therapy use, social support, and attitudes towards menopause and aging. we will combine this information with information from women's medical charts to look at how menopause and health related quality of life impact the use of health care resources. additionally, some women may be asked about the use of health care resources, such as doctor's visits, hospitalizations and lab tests.

Eligibility criteria:
inclusion criteria: * women ages 40-65 * patients in the university of pittsburgh general internal medicine oakland practice * able to complete the functional assessment screening tablet (a touch-screen survey) exclusion criteria: * refusal to participate

Keywords: menopause quality of life health services complementary therapies
dailies total 1 sphere contact lenses

Conditions: Dry Eye; Contact Lens Complication

Summary: cl discomfort is a complex phenomenon that has been defined by the tear film and ocular surface society in their seminal report on contact lens (cl) discomfort as a condition that results in "episodic or persistent adverse ocular sensation related to lens wear, either with or without visual disturbance resulting from reduced compatibility between the cl and the environment, which can lead to decreased wearing time and discontinuation of cl wear." a recent review by pucker and tichenor found that cl discomfort was the top reason for established cl wears to cease wearing cls. this same review alarmingly found that the frequency of cl dropout was about 20% across the many studies aimed at evaluating this condition, which is surprising given the introduction of better soft cl materials and daily disposable cls over the past 20 plus years. dailies total1 (dt1), which is a relatively new daily disposable cl, is a commonly used trouble shooting cl for patients who have failed with other cls because dt1 utilizes advanced material technology that is specifically aimed at improving cl comfort. while dt1 is commonly used in these struggling patients, the literature currently lacks a targeted study aimed at understanding the frequency of successfully refitting cl dropouts into this advanced cl. thus, the purpose of this study is to determine the frequency that past cl wearers who failed because of dryness or cl discomfort who can comfortable wear dt1.


Eligibility criteria:
inclusion criteria: * adults 18-40 * past contact lens wearers who have best corrected 20/20 visual acuity or better * participants will have had to have worn contact lenses for at least 1 year in the past * dropped out of contact lenses in the past 2 years do to discomfort or dryness * scores of 3 or less on the speed questionnaire * be able to be refit into dailies total1 sphere contact lenses * provide a glasses prescription that is less than 3-years-old exclusion criteria: * past rigid contact lens wearers * a past history of being diagnosed with dry eye or ocular allergies * known systemic health conditions that are known to alter tear film physiology * history of viral eye disease * history of ocular surgery * history of severe ocular trauma * history of corneal dystrophies or degeneration * having active ocular infection or inflammation * currently using isotretinoin-derivatives or ocular medication * pregnant or breast feeding

Keywords: contact lens dailies total1 dry eye comfort